IQ4I Research has published Emerging Isotopes Pipeline Analysis and Global Market

“Emerging Isotopes Pipeline Analysis and Global Market – Forecast to 2029” gives comprehensive insights on the various emerging isotope based candidates being developed for the both diagnosis as well as treatment of various cancers and non-cancer indications. The report covers marketed products details (Lutathera and Pluvito) and also candidates that are in various phases of development (Preclinical, Phase 1, Phase 2 & Phase 3). The pipeline focuses on diagnostic isotopes (Ga-68, Zr-89, Cu-64 and Pb-203) and therapeutic isotopes, (Ac-225, Pb-212, At-211, Ra-223, Th-227, Lu-177, Y-90, Re-188, Re-186, Cu-67, and Ho-166).

In case of Lu-177, Ga-68, Zr-89 and Cu-64, the report covers the patient population, treatment cost, total addressable market and penetration analysis for GEP-NET, Prostate cancer and Renal cancer. The pipeline analysis covers detailed analysis of name of candidates, list of companies, universities, and hospitals that are developing these agents, phase of development, nature of molecule, targets, and indications.

This report enables Pharmaceutical/Biotech companies, Academic institutes, Individual researchers, Investors, Medical technology companies, Service providers and other associated stake holders to identify and analyze the available licensing/collaborative commercial opportunities in the emerging isotopes global market. The report also provides strategic insights on some of the molecules which will eventually be launched in the next few years.

  • Market Analysis
  • In market analysis, global GEP-NET, Prostate cancer and Renal cancer market are indicated along with the Ga-68, Cu-64 and Zr-89 diagnostics market, and Lu-177 therapy market size, eligible patients pool, total addressable market (TAM), market penetration, opportunity and demand for Emerging Isotope is forecasted from 2021 to 2029.
  • Emerging Isotopes related deals analysis.
  • Global, N.A., Europe, APAC and RoW prevalence rates (GEP-NET, Prostate and Renal cancer).
  • Pipeline Analysis
  • Pipeline Analysis based Isotopes
  • Pipeline Analysis based on indications
  • Pipeline analysis based on targets
  • Pipeline analysis based on leading players
  • Key Players Analysis
  • The key player’s analysis section provides an in-depth understanding of various companies working on Emerging Isotopes and their pipelines with development phase as well as understanding partnering strategies such as deals entered by the company.
  • Key players overview
  • Key players Pipeline data (Pre-clinical, Phase 1, Phase 2 & Phase 3)
  • Key players deals (collaborations, partnership, licensing agreements, grants, funding etc.,)

Major players working on the emerging isotopes are Boston Scientific Corp. (U.S.) Clarity Pharmaceuticals (Australia), Curium SAS (France), Eckert & Ziegler (Pentixapharm) (Germany), Fusion Pharmaceuticals (Canada), Novartis International AG (Switzerland), ITM (Isotope Technologies Munich) (Germany), Orano Med, LLC (U.S.), Plus Therapeutics (U.S.), Point Biopharma (U.S.), RadioMedix, Inc. (U.S.) and Telix Pharmaceuticals (Australia).

Please visit our website:https://iq4i.com/reports/emerging-isotopes-pipeline-analysis-and-global-market-forecast-to-2029

write to us: This email address is being protected from spambots. You need JavaScript enabled to view it.

Phone: +91-8147030229

GM2 Gangliosidosis drugs are in phase 1 which will boost the market during the forecast period

GM2 Gangliosidosis, often known as Tay-Sachs disease, is caused by a mutation in the HEXA genes, which results in muscular atrophy. Because this disease has no known cure, therapy is mainly symptom-based. Some of the signs and symptoms include exaggerated reactions to loud noises, seizures, loss of movement, vision, and hearing, mucus collection in the lungs, and other symptoms. Tay-Sachs disease is also known as hexosaminidase disease. A deficiency is a rare inherited neurological disease caused by a loss of the enzyme hexosaminidase A, which results in the accumulation of G2 gangliosides.

The report " Global GM2 Gangliosidosis Market, By Type (Infantile, Juvenile and Adult), By Therapeutics (Enzymatic augmentation, Bone marrow transplantation, Enzyme enhancement and Substrate reduction therapy), By Drugs (Anticonvulsant, Antipsychotic medication and Others), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030”

Key Highlights:

  • Axovant Sciences, Inc. released clinical data for AXO-AAV-GM2, a gene therapy for Tay-Sachs disease, in March 2019. In a 30-month-old kid with advanced infantile Tay-Sachs disease, the trial showed that it was well tolerated with no significant adverse effects.
  • IntraBio Inc. submitted an Investigational New Drug (IND) application to the FDA in February 2019 for IB1001-202 to treat Tay-Sachs and Sandhoff Disease. The IND approval is a huge step forward for both the patients and the researchers.

Analyst View:

The market's expansion is due to the rising occurrence of genetic disease, particularly among newborns. Additionally, increased investment in R&D activities to develop new treatment options to cure the genetic disorder, as well as the release of new and improved medications to treat the disease's symptoms and consequences, are likely to propel market growth. The industry could be boosted by high demand for disease-specific novel treatments. Market growth is being boosted by the release of drugs to treat GM2 Gangliosidosis-related problems.

Browse 60 market data tables* and 35 figures* through 140 slides and in-depth TOC on “Global GM2 Gangliosidosis Market, By Type (Infantile, Juvenile and Adult), By Therapeutics (Enzymatic augmentation, Bone marrow transplantation, Enzyme enhancement and Substrate reduction therapy), By Drugs (Anticonvulsant, Antipsychotic medication and Others), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030”

To know the upcoming trends and insights prevalent in this market, click the link below:

https://www.prophecymarketinsights.com/market_insight/Global-GM2-Gangliosidosis-Market-4727

Key Market Insights from the report:

The Global GM2 Gangliosidosis Market is segmented based on the type, therapeutic, drugs, and region.

  • By Type, the Global GM2 Gangliosidosis Market is segmented into Infantile, Juvenile and Adults.
  • By Therapeutic, the market is segmented in Enzymatic augmentation, Bone marrow transplantation, Enzyme enhancement and Substrate reduction therapy.
  • By Drugs, the Global GM2 Gangliosidosis Market is segmented into Anticonvulsant, Antipsychotic medication and Others.
  • By Region, the Global GM2 Gangliosidosis Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. the market in North America is expected to increase significantly.

Competitive Landscape:

The key players operating in the global GM2 Gangliosidosis market includes Pfizer, Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, AstraZeneca, Novartis AG, and others. Recursion Pharmaceuticals, Inc., IntraBio Inc., Johnson & Johnson Services, Inc., and Axovant Sciences, Inc.

The market provides detailed information regarding the industrial base, productivity, strengths, manufacturers, and recent trends which will help companies enlarge the businesses and promote financial growth. Furthermore, the report exhibits dynamic factors including segments, sub-segments, regional marketplaces, competition, dominant key players, and market forecasts. In addition, the market includes recent collaborations, mergers, acquisitions, and partnerships along with regulatory frameworks across different regions impacting the market trajectory. Recent technological advances and innovations influencing the global market are included in the report.

About Prophecy Market Insights

Prophecy Market Insights is specialized market research, analytics, marketing/business strategy, and solutions that offers strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high-value opportunities in the target business area. We also help our clients to address business challenges and provide the best possible solutions to overcome them and transform their business.

Some Important Points Answered in this Market Report Are Given Below:

  • Explains an overview of the product portfolio, including product development, planning, and positioning.
  • Explains details about key operational strategies with a focus on R&D strategies, corporate structure, localization strategies, production capabilities, and financial performance of various companies.
  • Detailed analysis of the market revenue over the forecasted period.
  • Examining various outlooks of the market with the help of Porter’s five forces analysis, PEST & SWOT Analysis.
  • Study on the segments that are anticipated to dominate the market.
  • Study on the regional analysis that is expected to register the highest growth over the forecast period. 

Key Topics Covered

  1. Introduction
  • Study Deliverables
  • Study Assumptions
  • Scope of the Study
  1. Research Methodology
  2. Executive Summary
  • Opportunity Map Analysis
  • Market at Glance
  • Market Share (%) and BPS Analysis, by Region
  • Competitive Landscape
  • Heat Map Analysis 
  • Market Presence and Specificity Analysis
  1. Investment Analysis
  2. Competitive Analysis

To know more

Contact Us:

Sales

Prophecy Market Insights

  1 860 531 2701

Email- This email address is being protected from spambots. You need JavaScript enabled to view it.

Hetero Healthcare Set to Supply COVID19 Drug Remdesivir Under Brand Name COVIFOR

 Hetero’s group company ‘Hetero Healthcare Limited’ is all set to supply 20,000 vials of Covifor(Remdesivir) across the country.


Hyderabad, India; 24th June 2020: Following the approval of ‘COVIFOR’, the generic of Remdesivir by DCGI, Hetero Healthcare Limited, a group company of Hetero is set to deliver the first set of 20,000 vials in two equal lots of 10,000 each, one of which, will be immediately supplied to Hyderabad, Delhi, Gujarat, Tamil Nadu, Mumbai and other parts of Maharashtra; while the other lot will be supplied to Kolkata, Indore, Bhopal, Lucknow, Patna, Bhubaneshwar, Ranchi, Vijayawada, Cochin, Trivandrum and Goa within a week’s time, in order to meet the emergency requirements.

Mr. M. Srinivasa Reddy, Managing Director, Hetero Healthcare Limited said: “The launch of COVIFOR in India is a significant milestone for all of us. Hetero Healthcare has always been at the forefront in addressing public health emergencies. Through Covifor, we hope to reduce the treatment time of a patient in a hospital, thereby reducing the increasing pressure on the medical infrastructure, overburdened currently due to accelerating COVID-19 infection rates. We are working closely with the Government and Medical Community to make ‘Covifor’ quickly accessible to both public and private healthcare settings across the country.”

Covifor is the first generic brand of Remdesivir which is indicated for the treatment of COVID-19 patients in adults and children, hospitalized with severe symptoms of the disease. The drug is available in 100 mg vial (Injectable). It needs to be administered intravenously in a hospital, critical care setting, under the supervision of a registered medical practitioner. Covifor is anticipated to play a significant role in bringing down the mortality rates caused by COVID-19, given its proven positive clinical outcomes.

 

About Hetero Healthcare

Established in 1994, Hetero Healthcare Limited is a group company of Hetero which is engaged in the marketing and distribution of medicines in the Indian market. The company has a strong presence in India with 11 specialized marketing divisions and has been a market leader in ARV, Oncology, anti-flu anti-bacterial. With the team of 3200+ field force, Hetero Healthcare caters to medical practitioners in over 400 territories across India.

For Enquiries

  • Visit http://www.heterohealthcare.com/covifor-100mg-injection
  • Hospitals can place their orders by sending an e-mail to This email address is being protected from spambots. You need JavaScript enabled to view it.
  • Patients can reach out to Hetero Healthcare Team either through toll-free no.: 1800 1034 696 or through WhatsApp on +91 9320985814

Patent Agency Kipa Shifts Focus Back to Medical Devices



KIPA (Krahbichler Intellectual Property Advisors) has earned a reputation as one of the best IP firms for providing highly specialized professional advice to the medical device industry. Now KIPA provides quality IP services for diverse clients involved with innovations in several technological fields.

 

With the ongoing Covid-19 situation there has been an increased interest in developing medical technologies.

 

In order to aid this commendable effort KIPA is going back to its roots and is inviting any developers of medical devices or technologies to come to KIPA for help with securing the intellectual property side of this new push.

 

The world has handled this pandemic fairly well. One thing that is certain is that when the next global medical event takes place the world will be more ready than ever.

 

With 13 years of experience with aiding the medical device industries IP needs you can be sure that KIPA is up to the challenge. KIPA handles cases for clients ranging from startups to major industries and universities. 

 

Should you have any questions or concerns regarding the development of new medical technologies KIPA will have the answer. A great start for any new technology is a freedom to operate analysis to ensure that your technology will reach the market without unnecessary delays.

 

Statement from CEO Erik Krahbichler “We look forward to assist our existing and future clients in these challenging times. Strong IP protection has proven to support and strengthen the development of medical devices. This is for sure also valid for medical devices assisting Covid-19 patients and to fight the Coronavirus globally.”

 

KIPA (Krahbichler Intellectual Property Advisors) is an European IP boutique working with global clients. KIPA is specialized in medical technology (medtech) but handle any kind of IP cases. KIPA is experienced with prosecutions, litigations, oppositions as well as trademarks.

 

###

 

If you want more information about KIPA please contact KIPA at This email address is being protected from spambots. You need JavaScript enabled to view it..

 

For press enquiries contact This email address is being protected from spambots. You need JavaScript enabled to view it.

 

KIPA AB 

Drottninggatan 11

SE-252 21 Helsingborg

SWEDEN

VAT No. SE556713724401

Courageous Parents Network Addresses the Clinical Trial Option

Boston, MA, February 25, 2020 -- Courageous Parents Network (CPN), a 501(c)(3) nonprofit organization and digital platform bringing educational resources to families and medical providers caring for seriously ill children, today announced the release of a new digital unit, “Evaluating the Clinical Trial Option.” Timed to mark the observance of worldwide Rare Disease Day on Saturday, Feb. 29, the new unit employs documents, podcasts and video interviews to help families navigate consideration of clinical trial participation. 

Great Hope of Treatment--With Potential Pitfalls


According to CPN Founder and Executive Director Blyth Taylor Lord, a bereaved parent whose child suffered from a fatal disease, the fast-evolving landscape of potential new therapies and associated clinical trials offers great hope of treatments. Rare Disease Day, she says, will celebrate the many accomplishments and promise of new innovations in the pipeline. At the same time, she notes, “these new developments come along with potential for grief, if the child is not accepted into a trial or if the new treatment does not perform as hoped.

“Not understanding the process, with all of its implications, can leave the family vulnerable to new heartbreak. While every parent will be thinking about what participation may mean for their own child, the trial process is about advances for the greater good--the benefits to many. One of our goals is to 

present a clear-eyed picture, through the lens of families and medical professionals, to empower parents 
and their children to make choices that work with their values.” 

“Evaluating the Clinical Trial Option” Content
Sample content from CPN “Evaluating the Clinical Trial Option” unit includes

  • Video excerpts from parent interviews, revealing the hopes, dreams and fears of families 

  • Video excerpts from interviews with a principal investigator, trial coordinator, and a family services director—and “sound stories” (podcasts) that explain the process, along with potential risks and rewards 

  • Blog posts

  • Supplementary downloadable guides, providing reference information specific to family questions, needs and concerns

The unit, which is available free of charge, 24/7, to families and providers, is funded in part through the support of Sanofi Genzyme, Bridgebio, Aspa Therapeutics, AveXis, BioMarin, bluebird bio, REGENXBIO and Amicus Therapeutics.  

Meeting a Critical Need

According to National Tay-Sachs and Related Disease (NTSAD) Director, Family Services Diana Pangonis, [We must be prepared to] “guide those families that face the challenges of participating, and comfort those families who are reliving the enormity of grief as they learn their child will not be included in a trial. We are pleased that CPN has taken on the task of creating an entire unit devoted to the social-emotional aspects connected to clinical trials in the rare disease space.”

Dawn Mariano, mother of Vayle, added, ““These resources remind you that there are others going through this journey with you, navigating life with a medically fragile child. Hearing other parents’ stories, their hopes and fears, you know you’re not alone, and you can be comforted knowing there is a network, a community, working so hard for you and your precious child.”

Available Free of Charge, 24/7

To view and explore “Evaluating the Clinical Trial Option” visit https://courageousparentsnetwork.org/topics/clinical-trial

About Courageous Parents Network

CPN is a 501(c)(3) whose mission is to empower, support and equip families and providers caring for children with serious illness. CPN’s vision promotes the family's journey as one in which they have confidence in their ability to be the best caregivers they can possibly be, resulting in minimal regret and maximal healing; and that pediatric medical providers feel increased success in delivering family-centered care. For more information visit CourageousParentsNetwork.org.

CPN stacked logo